{"transactions":[{"id":4625548,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-23T20:54:08.000Z","date":"2026-09-21","kind":"sale","planned":false,"acquired":false,"shares":87,"price":2.9742,"value":258.7554,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":11160,"source":{"system":"sec-edgar","filing":"0001609284-26-000005","document":"form4-09232026_080903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000160928426000005/form4-09232026_080903.xml","form_type":"4"}},{"id":690343,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":542232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":542232,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":542232},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690342,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":542232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":542232},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690341,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":16898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":16898,"derivative":{"exercise_price":4.14,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":16898},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690340,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":16898},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690339,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":8449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":8449,"derivative":{"exercise_price":4.14,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":8449},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690338,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":8449},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690337,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":1485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":1485,"derivative":{"exercise_price":4.14,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":1485},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690336,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":1485},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690335,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":2359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":2359,"derivative":{"exercise_price":4.14,"expiration_date":"2032-01-03","underlying":"Class A Common Stock","underlying_shares":2359},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690334,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":21.2,"expiration_date":"2032-01-10","underlying":"Class A Common Stock","underlying_shares":2359},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690333,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":150000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":727410,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2026-06-24T23:29:18.000Z","date":"2026-06-22","kind":"sale","planned":false,"acquired":false,"shares":86,"price":4.3963,"value":378.0818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026."}],"balance_after":11247,"source":{"system":"sec-edgar","filing":"0001609284-26-000003","document":"form4-06242026_110612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000003/form4-06242026_110612.xml","form_type":"4"}},{"id":815640,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-03T19:29:11.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":330000,"derivative":{"exercise_price":4.07,"expiration_date":"2036-03-31","underlying":"Class A Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001609284-26-000002","document":"form4-04032026_070404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000002/form4-04032026_070404.xml","form_type":"4"}},{"id":828987,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2026-03-24T22:57:58.000Z","date":"2026-03-23","kind":"sale","planned":false,"acquired":false,"shares":86,"price":4.1565,"value":357.459,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":7333,"source":{"system":"sec-edgar","filing":"0001609284-26-000001","document":"form4-03242026_100353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000001/form4-03242026_100353.xml","form_type":"4"}},{"id":959350,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-12-24T01:09:47.000Z","date":"2025-12-22","kind":"sale","planned":false,"acquired":false,"shares":87,"price":2.9677,"value":258.1899,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025."}],"balance_after":7419,"source":{"system":"sec-edgar","filing":"0001609284-25-000004","document":"form4-12242025_011243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928425000004/form4-12242025_011243.xml","form_type":"4"}},{"id":1032839,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-09-24T23:42:17.000Z","date":"2025-09-22","kind":"sale","planned":false,"acquired":false,"shares":88,"price":2.6235,"value":230.868,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":3506,"source":{"system":"sec-edgar","filing":"0001609284-25-000003","document":"form4-09242025_110912.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928425000003/form4-09242025_110912.xml","form_type":"4"}},{"id":1101501,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-06-25T22:52:16.000Z","date":"2025-06-23","kind":"sale","planned":false,"acquired":false,"shares":88,"price":2.3842,"value":209.8096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001415889-25-018235","document":"form4-06252025_100613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925018235/form4-06252025_100613.xml","form_type":"4"}},{"id":1175212,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-04-08T21:32:14.000Z","date":"2025-04-07","kind":"sale","planned":false,"acquired":false,"shares":516,"price":2.671,"value":1378.236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":3682,"source":{"system":"sec-edgar","filing":"0001415889-25-010419","document":"form4-04082025_090410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925010419/form4-04082025_090410.xml","form_type":"4"}},{"id":1175211,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-04-08T21:32:14.000Z","date":"2025-04-04","kind":"sale","planned":false,"acquired":false,"shares":358,"price":3.3276,"value":1191.2808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":4198,"source":{"system":"sec-edgar","filing":"0001415889-25-010419","document":"form4-04082025_090410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925010419/form4-04082025_090410.xml","form_type":"4"}},{"id":1291658,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-30T01:36:23.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":130000,"derivative":{"exercise_price":5.19,"expiration_date":"2035-01-26","underlying":"Class A Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-002312","document":"form4-01302025_010119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925002312/form4-01302025_010119.xml","form_type":"4"}},{"id":1389074,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":542232,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":542232,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":542232},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389073,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":8449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":8449,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":8449},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389072,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":16898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":16898,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":16898},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389071,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":1485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":1485,"derivative":{"exercise_price":13.99,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":1485},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389070,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":2359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/12th of the shares subject to the option vested on March 31, 2022 and 1/12th of the shares subject to the option vest on the last day of each quarter thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":2359,"derivative":{"exercise_price":21.2,"expiration_date":"2032-01-10","underlying":"Class A Common Stock","underlying_shares":2359},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389069,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":4556,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a \"Service-Based Requirement\" and a \"Liquidity Event Plus Service Requirement.\" 1/16th of the RSUs met the \"Service-Based\" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo Pharmaceuticals, Inc. (\"Reneo\"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo (\"Merger Sub I\"), and OnKure, Inc. (\"OnKure\"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the \"Merger\"). After completion of the Merger, the combined company was renamed \"OnKure Therapeutics, Inc.\" and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol \"OKUR.\""},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a \"Service-Based Requirement\" and a \"Liquidity Event Plus Service Requirement.\" 1/16th of the RSUs met the \"Service-Based\" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo Pharmaceuticals, Inc. (\"Reneo\"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo (\"Merger Sub I\"), and OnKure, Inc. (\"OnKure\"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the \"Merger\"). After completion of the Merger, the combined company was renamed \"OnKure Therapeutics, Inc.\" and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol \"OKUR.\""}],"balance_after":4556,"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":3453483,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:52.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":138000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option provided for vesting in four equal annual installments beginning on December 16, 2019."}],"balance_after":0,"derivative":{"exercise_price":15.97,"expiration_date":"2028-12-16","underlying":"Common Stock","underlying_shares":138000},"source":{"system":"sec-edgar","filing":"0001209191-19-043783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043783/doc4.xml","form_type":"4"}},{"id":3453482,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:52.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":168000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option provided for vesting in four equal annual installments beginning on December 16, 2018."}],"balance_after":0,"derivative":{"exercise_price":10.92,"expiration_date":"2027-12-16","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001209191-19-043783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043783/doc4.xml","form_type":"4"}},{"id":3453481,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:52.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":131250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option provided for vesting in four equal annual installments beginning on December 26, 2017."}],"balance_after":0,"derivative":{"exercise_price":8.79,"expiration_date":"2026-12-27","underlying":"Common Stock","underlying_shares":131250},"source":{"system":"sec-edgar","filing":"0001209191-19-043783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043783/doc4.xml","form_type":"4"}},{"id":3453480,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:52.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":82500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option provided for vesting in four equal annual installments beginning on April 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":3,"expiration_date":"2026-04-01","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001209191-19-043783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043783/doc4.xml","form_type":"4"}},{"id":3453479,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:52.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":165000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option provided for vesting in four equal annual installments beginning on April 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":7.3,"expiration_date":"2025-04-01","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-19-043783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043783/doc4.xml","form_type":"4"}},{"id":3453478,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-07-30T20:04:52.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":61813,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares of Company common stock underlying each restricted stock unit (a \"Company RSU\") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-043783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043783/doc4.xml","form_type":"4"}},{"id":3453477,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-07-30T20:04:52.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":150190,"price":48,"value":7209120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."}],"balance_after":61813,"source":{"system":"sec-edgar","filing":"0001209191-19-043783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043783/doc4.xml","form_type":"4"}},{"id":3565841,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2019-04-03T16:30:54.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016."}],"balance_after":6875,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001562180-19-002182","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002182/primarydocument.xml","form_type":"4"}},{"id":3565840,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2019-04-03T16:30:54.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001562180-19-002182","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002182/primarydocument.xml","form_type":"4"}},{"id":3565839,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-04-03T16:30:54.000Z","date":"2019-04-01","kind":"tax_withholding","acquired":false,"shares":6048,"price":24.6,"value":148780.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":150190,"source":{"system":"sec-edgar","filing":"0001562180-19-002182","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002182/primarydocument.xml","form_type":"4"}},{"id":3565838,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-04-03T16:30:54.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted on April 1, 2015 and April 1, 2016, as a result of the vesting of one fourth of such RSUs."}],"balance_after":156238,"source":{"system":"sec-edgar","filing":"0001562180-19-002182","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002182/primarydocument.xml","form_type":"4"}},{"id":3668764,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T18:32:46.000Z","date":"2019-02-07","kind":"exercise","acquired":false,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in four equal annual installments beginning on April 1, 2017."}],"balance_after":82500,"derivative":{"exercise_price":3,"expiration_date":"2026-04-01","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001562180-19-000860","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000860/primarydocument.xml","form_type":"4"}},{"id":3668763,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T18:32:46.000Z","date":"2019-02-07","kind":"exercise","acquired":false,"shares":104764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in four equal annual installments beginning May 30, 2015."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2024-05-30","underlying":"Common Stock","underlying_shares":104764},"source":{"system":"sec-edgar","filing":"0001562180-19-000860","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000860/primarydocument.xml","form_type":"4"}},{"id":3668762,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-02-08T18:32:46.000Z","date":"2019-02-07","kind":"sale","acquired":false,"shares":187264,"price":21.5832,"value":4041756.3648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for these shares is the weighted average sale price of transactions made at prices from $21.50 to $21.785. Details of actual prices for shares sold are available from the Issuer upon request."}],"balance_after":142488,"source":{"system":"sec-edgar","filing":"0001562180-19-000860","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000860/primarydocument.xml","form_type":"4"}},{"id":3668761,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-02-08T18:32:46.000Z","date":"2019-02-07","kind":"exercise","acquired":true,"shares":104764,"price":4.2,"value":440008.8,"ownership":{"direct":true},"balance_after":329752,"source":{"system":"sec-edgar","filing":"0001562180-19-000860","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000860/primarydocument.xml","form_type":"4"}},{"id":3668760,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-02-08T18:32:46.000Z","date":"2019-02-07","kind":"exercise","acquired":true,"shares":82500,"price":3,"value":247500.0,"ownership":{"direct":true},"balance_after":224988,"source":{"system":"sec-edgar","filing":"0001562180-19-000860","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000860/primarydocument.xml","form_type":"4"}},{"id":3677918,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T16:28:54.000Z","date":"2019-01-31","kind":"exercise","acquired":false,"shares":95236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning May 30, 2015."}],"balance_after":104764,"derivative":{"exercise_price":4.2,"expiration_date":"2024-05-30","underlying":"Common Stock","underlying_shares":95236},"source":{"system":"sec-edgar","filing":"0001562180-19-000727","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000727/primarydocument.xml","form_type":"4"}},{"id":3677917,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-02-04T16:28:54.000Z","date":"2019-01-31","kind":"tax_withholding","acquired":false,"shares":21425,"price":18.67,"value":400004.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":142488,"source":{"system":"sec-edgar","filing":"0001562180-19-000727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000727/primarydocument.xml","form_type":"4"}},{"id":3677916,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2019-02-04T16:28:54.000Z","date":"2019-01-31","kind":"exercise","acquired":true,"shares":95236,"price":4.2,"value":399991.2,"ownership":{"direct":true},"balance_after":163913,"source":{"system":"sec-edgar","filing":"0001562180-19-000727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000727/primarydocument.xml","form_type":"4"}},{"id":3727443,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2018-12-18T19:49:05.000Z","date":"2018-12-16","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested and were settled in common stock on December 16, 2018."}],"balance_after":21000,"derivative":{"exercise_price":0,"expiration_date":"2021-12-17","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001562180-18-005030","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005030/primarydocument.xml","form_type":"4"}},{"id":3727442,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2018-12-18T19:49:05.000Z","date":"2018-12-16","kind":"exercise","acquired":false,"shares":5469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested and were settled in common stock on December 16, 2018."}],"balance_after":10938,"derivative":{"exercise_price":0,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":5469},"source":{"system":"sec-edgar","filing":"0001562180-18-005030","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005030/primarydocument.xml","form_type":"4"}},{"id":3727441,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-18T19:49:05.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":138000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in four equal annual installments beginning on December 16, 2019."}],"balance_after":138000,"derivative":{"exercise_price":15.97,"expiration_date":"2028-12-16","underlying":"Common Stock","underlying_shares":138000},"source":{"system":"sec-edgar","filing":"0001562180-18-005030","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005030/primarydocument.xml","form_type":"4"}},{"id":3727440,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2018-12-18T19:49:05.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019."}],"balance_after":23000,"derivative":{"exercise_price":0,"expiration_date":"2022-12-20","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001562180-18-005030","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005030/primarydocument.xml","form_type":"4"}},{"id":3727439,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2018-12-18T19:49:05.000Z","date":"2018-12-16","kind":"tax_withholding","acquired":false,"shares":5485,"price":15.97,"value":87595.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":68677,"source":{"system":"sec-edgar","filing":"0001562180-18-005030","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005030/primarydocument.xml","form_type":"4"}},{"id":3727438,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2018-12-18T19:49:05.000Z","date":"2018-12-16","kind":"exercise","acquired":true,"shares":12469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs."}],"balance_after":74162,"source":{"system":"sec-edgar","filing":"0001562180-18-005030","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005030/primarydocument.xml","form_type":"4"}},{"id":3880635,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2018-06-29T16:22:36.000Z","date":"2018-06-27","kind":"exercise","acquired":false,"shares":11453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs representing 11,453 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2018-08-18","underlying":"Common Stock","underlying_shares":11453},"source":{"system":"sec-edgar","filing":"0001562180-18-003131","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003131/primarydocument.xml","form_type":"4"}},{"id":3880634,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2018-06-29T16:22:36.000Z","date":"2018-06-27","kind":"tax_withholding","acquired":false,"shares":5038,"price":18.5,"value":93203.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":61693,"source":{"system":"sec-edgar","filing":"0001562180-18-003131","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003131/primarydocument.xml","form_type":"4"}},{"id":3880633,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2018-06-29T16:22:36.000Z","date":"2018-06-27","kind":"exercise","acquired":true,"shares":11453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares released on vesting of Restricted Stock Units (\"RSUs\") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II."}],"balance_after":66731,"source":{"system":"sec-edgar","filing":"0001562180-18-003131","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003131/primarydocument.xml","form_type":"4"}},{"id":3973811,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2018-04-03T18:48:58.000Z","date":"2018-04-01","kind":"exercise","acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The remaining RSUs vest and will be settled in stock in two equal annual installments on April 1, 2019 and 2020."}],"balance_after":13750,"derivative":{"exercise_price":0,"expiration_date":"2020-04-01","underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001562180-18-001803","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018001803/primarydocument.xml","form_type":"4"}},{"id":3973810,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2018-04-03T18:48:58.000Z","date":"2018-04-01","kind":"tax_withholding","acquired":false,"shares":6118,"price":16.32,"value":99845.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":55278,"source":{"system":"sec-edgar","filing":"0001562180-18-001803","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018001803/primarydocument.xml","form_type":"4"}},{"id":3973809,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2018-04-03T18:48:58.000Z","date":"2018-04-01","kind":"exercise","acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by the Issuer on April 1, 2016 as a result of the vesting of one fourth of such RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 6,875 unvested Restricted Stock Units (\"RSUs\") awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and (ii) 6,875 shares of common stock issued upon the vesting of these RSU's on April 1, 2018."}],"balance_after":61396,"source":{"system":"sec-edgar","filing":"0001562180-18-001803","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018001803/primarydocument.xml","form_type":"4"}},{"id":4126826,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-19T21:05:17.000Z","date":"2017-12-16","kind":"grant","acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in four equal annual installments beginning on December 16, 2018."}],"balance_after":168000,"derivative":{"exercise_price":10.92,"expiration_date":"2027-12-16","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001562180-17-003956","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003956/primarydocument.xml","form_type":"4"}},{"id":4126825,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2017-12-19T21:05:17.000Z","date":"2017-12-16","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018."}],"balance_after":28000,"derivative":{"exercise_price":0,"expiration_date":"2021-12-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001562180-17-003956","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003956/primarydocument.xml","form_type":"4"}},{"id":4126824,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2017-12-19T21:05:17.000Z","date":"2017-12-16","kind":"exercise","acquired":false,"shares":5468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested on December 16, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person."}],"balance_after":16407,"derivative":{"exercise_price":0,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":5468},"source":{"system":"sec-edgar","filing":"0001562180-17-003956","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003956/primarydocument.xml","form_type":"4"}},{"id":4126823,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:17.000Z","date":"2017-12-16","kind":"tax_withholding","acquired":false,"shares":2548,"price":10.92,"value":27824.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":54521,"source":{"system":"sec-edgar","filing":"0001562180-17-003956","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003956/primarydocument.xml","form_type":"4"}},{"id":4126822,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:17.000Z","date":"2017-12-16","kind":"exercise","acquired":true,"shares":5468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 13,750 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs."}],"balance_after":57069,"source":{"system":"sec-edgar","filing":"0001562180-17-003956","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003956/primarydocument.xml","form_type":"4"}},{"id":4356966,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2017-04-06T20:31:45.000Z","date":"2017-04-01","kind":"tax_withholding","acquired":false,"shares":6543,"price":8.94,"value":58494.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. The ending balance has also been corrected to include 2,332 shares purchased pursuant to the issuer's Employee Stock Purchase Plan on December 31, 2016. No other information in such form 4 is being amended."}],"balance_after":37851,"source":{"system":"sec-edgar","filing":"0001562180-17-001486","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001486/primarydocument.xml","form_type":"4/A","original_submission_date":"2017-04-04"}},{"id":4362045,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2017-04-04T21:42:56.000Z","date":"2017-04-01","kind":"exercise","acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Consists of unvested RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person."}],"balance_after":20625,"derivative":{"exercise_price":0,"expiration_date":"2020-04-01","underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001562180-17-001465","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001465/primarydocument.xml","form_type":"4"}},{"id":4362044,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2017-04-04T21:42:56.000Z","date":"2017-04-01","kind":"tax_withholding","acquired":false,"shares":4535,"price":8.94,"value":40542.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person."}],"balance_after":37526,"source":{"system":"sec-edgar","filing":"0001562180-17-001465","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001465/primarydocument.xml","form_type":"4"}},{"id":4362043,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Common Stock","published_at":"2017-04-04T21:42:56.000Z","date":"2017-04-01","kind":"exercise","acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of Restricted Stock Units (\"RSUs\") granted to the reporting person, of which 2,152 shares were withheld upon vesting to satisfy tax withholding obligations.The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 13,750 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and 2,332 shares purchased pursuant to the issuer's Employee Stock Purchase Plan on December 31, 2016."}],"balance_after":42061,"source":{"system":"sec-edgar","filing":"0001562180-17-001465","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001465/primarydocument.xml","form_type":"4"}},{"id":4510699,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-29T17:53:03.000Z","date":"2016-12-27","kind":"grant","acquired":true,"shares":131250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on December 16, 2017."}],"balance_after":131250,"derivative":{"exercise_price":8.79,"expiration_date":"2026-12-27","underlying":"Common Stock","underlying_shares":131250},"source":{"system":"sec-edgar","filing":"0001562180-16-003919","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003919/primarydocument.xml","form_type":"4"}},{"id":4510698,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO"}}],"security":"Restricted Stock Units","published_at":"2016-12-29T17:53:03.000Z","date":"2016-12-27","kind":"grant","acquired":true,"shares":21875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2017."}],"balance_after":21875,"derivative":{"exercise_price":0,"expiration_date":"2020-12-28","underlying":"Common Stock","underlying_shares":21875},"source":{"system":"sec-edgar","filing":"0001562180-16-003919","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003919/primarydocument.xml","form_type":"4"}}]}